- Home
- RAAQ vs VYGR Comparison
RAAQ vs VYGR Comparison
Compare RAAQ & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RAAQ | VYGR |
|---|---|---|
| Founded | 2024 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 240.3M | 194.0M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | RAAQ | VYGR |
|---|---|---|
| Price | $10.62 | $3.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $21.00 |
| AVG Volume (30 Days) | 217.1K | ★ 845.7K |
| Earning Date | 01-01-0001 | 06-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,135,000.00 |
| Revenue This Year | N/A | $54.19 |
| Revenue Next Year | N/A | $20.22 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.62 | $2.65 |
| 52 Week High | $10.80 | $5.55 |
Technical Indicators
Market Signals| Indicator | RAAQ | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 55.38 | 44.39 |
| Support Level | $10.22 | $3.60 |
| Resistance Level | $10.73 | $4.43 |
| Average True Range (ATR) | 0.11 | 0.33 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 40.33 | 7.73 |
Price Performance
Historical ComparisonAbout RAAQ Real Asset Acquisition Corp. Class A Ordinary Share
Real Asset Acquisition Corp is a blank check company.
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.